The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload
Open accessAbstract
Congestive heart failure is a leading cause of mortality in developed countries. Myocardial hypertrophy resulting from hypertension often precedes heart failure. Understanding the signaling underlying cardiac hypertrophy and failure is of major interest. Here, we identified Fas receptor activation, a classical death signal causing apoptosis via activation of the caspase cascade in many cell types, as a novel pathway mediating cardiomyocyte hypertrophy in vitro and in vivo. Fas activation by Fas ligand induced a hypertrophic response in cultured cardiomyocytes, which was dependent on the inactivation of glycogen synthase kinase 3 beta (GSK3 beta) by phosphorylation. In vivo, lpr (lymphoproliferative disease) mice lacking a functional Fas receptor demonstrated rapid-onset left ventricular dilatation and failure, absence of compensatory hypertrophy, and significantly increased mortality in response to pressure overload induction that was accompanied by a failure to inhibit GSK3 beta activity. In contrast, Fas ligand was dispensable for the development of pressure overload hypertrophy in vivo. In vitro, neonatal cardiomyocytes from lpr mice showed a completely abrogated or significantly blunted hypertrophic response after stimulation with Fas ligand or angiotensin II, respectively. These findings indicate that Fas receptor signaling inhibits GSK3 beta activity in cardiomyocytes and is required for compensation of pressure overload in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · cited 5×
“GSK3β is an established target of the PI3K/Akt signaling pathway with Akt phosphorylating and thereby inactivating GSK3β (19).”
BackgroundResultInfluentialActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · cited 1×
“Cells or tissue were homogenized in lysis buffer, and 25 μg was separated by SDS-PAGE, transferred to PVDF membranes, and immunoblotted as described (15).”
MethodSelf-citationApoptosis in Myocytes in End-Stage Heart Failure
Narula, J., Haider, N., Virmani, R., DiSalvo, T. G., Kolodgie, F. D., Hajjar, R. J., Schmidt, U., Semigran, M. J., Dec, G. W., & Khaw, B.-A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351603 · Cited by 1,430
Cited by
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
The Fas Signaling Pathway: More Than a Paradigm
Wajant, H. (2002) · Science · doi:10.1126/science.1071553 · Cited by 957
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Hypertrophy of the Heart: A New Therapeutic Target?
Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000120390.68287.bb · Cited by 851
Protein kinase cascades in the regulation of cardiac hypertrophy
Dorn, G. W., & Force, T. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524178 · Cited by 638
Badorff, C., Brandes, R. P., Popp, R., Rupp, S., Urbich, C., Aicher, A., Fleming, I., Busse, R., Zeiher, A. M., & Dimmeler, S. (2003) · Circulation · doi:10.1161/01.cir.0000051460.85800.bb · Cited by 531
Self-citationThe role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease
OUDIT, G. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.015 · Cited by 469
Glycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
The CD95 Receptor: Apoptosis Revisited
Peter, M. E., Budd, R. C., Desbarats, J., Hedrick, S. M., Hueber, A.-O., Newell, M. K., Owen, L. B., Pope, R. M., Tschopp, J., Wajant, H., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.031 · Cited by 395
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Brancaccio, M., Fratta, L., Notte, A., Hirsch, E., Poulet, R., Guazzone, S., De Acetis, M., Vecchione, C., Marino, G., Altruda, F., et al. (2003) · Nature Medicine · doi:10.1038/nm805 · Cited by 296
Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses
Choi, C., & Benveniste, E. N. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.08.007 · Cited by 270
Perrino, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25397 · Cited by 268
Nrf2 Protects Against Maladaptive Cardiac Responses to Hemodynamic Stress
Li, J., Ichikawa, T., Villacorta, L., Janicki, J. S., Brower, G. L., Yamamoto, M., & Cui, T. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.189480 · Cited by 253
Molecular Mechanisms in Heart Failure
Hilfiker-Kleiner, D., Landmesser, U., & Drexler, H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.007 · Cited by 151
Metadata
- Authors
- Badorff, C., Ruetten, H., Mueller, S., Stahmer, M., Gehring, D., Jung, F., Ihling, C., Zeiher, A. M., & Dimmeler, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-02-01
- Volume
- 109
- Issue
- 3
- Pages
- 373-381
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2053870616
- Cited by
- 174
- References
- 3
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.